Home / Private raises / 270 Life Sciences Private Capital Fund II (Cayman) LP
270 Life Sciences Private Capital Fund II (Cayman) LP
Venture Capital Fund · New York, New York · $0 sold across 1 offering
Form D filings (1)
| Filed | Form | Sold | Offered | Investors | Exemption | Securities | First sale | |
|---|---|---|---|---|---|---|---|---|
| 2026-09-16 | D (new) | $0 | Open-ended | 0 | 506(b), 3(c), 3(c)(1), 3(c)(7) | Fund interests | Not yet | SEC ↗ |
An update (D/A) restates the running total of its offering, so the total above counts each offering's latest figure once.
Sold through (placement agents)
| Broker-dealer | Solicited in |
|---|---|
| J.P. Morgan Securities LLC | All States |
| J.P. Morgan Institutional Investments Inc. | All States |
No sales commission reported in the latest filing.
Issuer
| Industry | Pooled Investment Fund |
| Fund type | Venture Capital Fund |
| Located | New York, New York |
| Entity | Limited Partnership |
| Incorporated | Cayman Islands, 2026 |
| SEC CIK | 2154213 |
People named in the latest filing
| Name | Role |
|---|---|
| 270 Life Sciences Private Capital Fund II GP Ltd. | Director |
| Gaurav Gupta | Executive Officer |
| Stephen Squinto | Executive Officer |
| Patrick McGoldrick | Executive Officer |
| Samantha Beattie | Executive Officer |
Names and roles as filed with the SEC. Addresses are not shown.
Source: SEC EDGAR Form D filings. Amounts are self-reported by the issuer. Not investment advice.
How are we doing?
